Consensus Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 13/10/2026 am IST			5-day change	1st Jan Change
2.080 ^USD	0.00%		+4.52%	+33.33%

06/10	Alector Shares Rise After Licensing AL050 Program to Roche's Genentech	MT
05/10	Alector, Inc. And Genentech, Inc. Enter Global License Agreement For Brain Penetrant GCase Enzyme Replacement Therapy For Parkinsons Disease And Other Neurodegenerative Diseases	CI

Evolution of the Average Target: Alector, Inc.

Evolution of the Target Price: Alector, Inc.

Changes in Analyst Recommendations: Alector, Inc.

97d774b6b2e0f2214d3e3.9JC0MbUdmRP2JpNMAlUl4s35314hNlBZA__bGGis8SY.uuj4Ut8l4yuRV9k1d2AXq7qelwFmYSkWVrLrUjDohlSg_NV_90_XV7xJyg~d2de3ce780b853a79942c8788a925a67

Analysts' recommendations: Alector, Inc.

16/04	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
15/04	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
11/03	Alector Shares Rise After BTIG Upgrade	MT
10/03	BTIG Upgrades Alector to Buy From Neutral, Price Target is $6	MT
22/25/22	Top Midday Decliners	MT
22/25/22	William Blair Downgrades Alector to Market Perform From Outperform	MT
22/25/22	TD Cowen Downgrades Alector to Hold From Buy	MT
22/25/22	BTIG Downgrades Alector to Neutral From Buy	MT
22/25/22	Cantor Fitzgerald Downgrades Alector to Neutral From Overweight	MT
22/25/22	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $1.50 From $3.50	MT
29/25/29	Alector Shares Rise After Mizuho Upgrade	MT
28/25/28	Mizuho Upgrades Alector to Outperform From Neutral, Raises Price Target to $3.50 From $2.50	MT
17/24/17	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9	MT
16/24/16	Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15	MT
04/24/04	BofA Securities Downgrades Alector to Underperform	MT
14/23/14	Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	MT
12/23/12	Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	MT
16/23/16	Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating	MT
22/23/22	Cantor Fitzgerald Starts Alector at Overweight With $13 Price Target	MT
11/23/11	Mizuho Cuts Price Target on Alector to $10 From $12, Keeps Buy Rating	MT
08/23/08	Stifel Adjusts Price Target on Alector to $8 From $10, Maintains Hold Rating	MT
05/23/05	Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating	MT
03/23/03	Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating	MT
02/23/02	BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating	MT
02/23/02	Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALECTOR, INC.					+58.65%
	WUXI APPTEC CO., LTD.					+20.84%
	ARGENX SE					+39.14%
	LONZA GROUP AG					+20.12%
	IQVIA HOLDINGS INC.					+12.53%
	REVOLUTION MEDICINES, INC.					+33.61%
	BEONE MEDICINES AG					+24.3%
	CELLTRION, INC.					+48.42%
	WUXI BIOLOGICS (CAYMAN) INC.					+12.92%
	BIONTECH SE					+20.9%
	Average					+29.14%
	Weighted average by Cap.					+25.76%